Dose-Dependent Effects of Rosuvastatin on the Plasma Sphingolipidome and Phospholipidome in the Metabolic Syndrome
Theodore WK Ng, Esther MM Ooi, Gerald F Watts, Dick C Chan, Jacquelyn M Weir, Peter J Meikle, P Hugh R Barrett
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | ENDOCRINE SOC | Published : 2014
CONTEXT: Statins are effective cholesterol-lowering agents that reduce cardiovascular disease risk but also have pleiotropic effects that may extend to other lipid classes. OBJECTIVE: The purpose of this article was to investigate, in a post hoc analysis, the dose-dependent effects of rosuvastatin on plasma sphingolipids and phospholipids in men with the metabolic syndrome. METHODS: Subjects (n = 12) were studied in a randomized, double-blind, triple-crossover trial of a 5-week treatment period with placebo or rosuvastatin (10 or 40 mg/day) with 2-week washouts between treatments. Plasma sphingolipid profiling was determined by liquid chromatography electrospray ionization-tandem mass spectr..View full abstract
This study was supported by grants from the National Heart Foundation of Australia, the National Health and Medical Research Council (NHMRC) of Australia, the Medical Research Fund of the Royal Perth Hospital, the OIS Program of the Victorian Government, and AstraZeneca Pty. Ltd. Australia. T.W.K.N. and E.M.M.O. are NHMRC Postdoctoral Research Fellows. D.C.C. is a Career Development Fellow of the NHMRC. P.J.M. and P.H.R. B. are NHMRC Senior Research Fellows.